Client case: Development of a Novel Antibody Drug Targeting IL-25 for Atopic Dermatitis(AD).Client: A pharmaceutical company developing a new antibody targeting the IL-25 pathway for the treatment of ADObjective: To establish the efficacy and safety of the new anti-IL-25 antibody in preclinical mode

Client No.1: Efficacy of Novel Compound in EAE Model Client Background:Our client is a pharmaceutical company that has developed a novel compound designed to target mitochondrial damage-related autophagy and possesses neuroregenerative properties. The client aims to explore the potential therapeutic